Gyre Therapeutics (GYRE) Raw Materials (2022 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Raw Materials of $1.2 million for Q1 2026, little changed year-over-year from $1.2 million in Q1 2025, and up 21.03% quarter-over-quarter from $970000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Raw Materials (2022 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Raw Materials for 5 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Raw Materials changed 0.43% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (changed 0.43% YoY), while the FY2025 annual figure was $970000.0, up 22.17% from the prior year.
- Raw Materials rose to $1.2 million in Q1 2026 per GYRE's latest filing, from $970000.0 in the prior quarter.
- Across five years, Raw Materials topped out at $1.2 million in Q2 2025 and bottomed at $724000.0 in Q1 2024.
- Historically, Raw Materials has averaged $1.0 million across 5 years, with a median of $1.1 million in 2022.
- Annual changes were most pronounced in 2024 — Raw Materials slipped 13.6% — and 2025, when it jumped 61.46%.
- Gyre Therapeutics' Raw Materials stood at $1.1 million in 2022, then declined by 12.97% to $919000.0 in 2023, then declined by 13.6% to $794000.0 in 2024, then increased by 22.17% to $970000.0 in 2025, then grew by 21.03% to $1.2 million in 2026.
- Business Quant data shows GYRE's Raw Materials at $1.2 million in Q1 2026, $970000.0 in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 774,000.00 |
| Mar 31, 2026 | 1.17 Mn |
| Dec 31, 2025 | 970,000.00 |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 794,000.00 |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.17 Mn |
| Mar 31, 2024 | 724,000.00 |
| Dec 31, 2023 | 919,000.00 |
| Dec 31, 2022 | 1.06 Mn |